Yi Jun Ho, Kim Seok Jin, Kim Won Seog
Division of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, Seoul, Korea.
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Blood Res. 2017 Dec;52(4):243-253. doi: 10.5045/br.2017.52.4.243. Epub 2017 Dec 26.
Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. Owing to the remarkable efficacy shown in CD30-positive lymphomas, such as Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma, BV was granted accelerated approval in 2011 by the US Food and Drug Administration. Thereafter, many large-scale trials in various situations have been performed, which led to extensions of the original indication. The aim of this review was to describe the latest updates on clinical trials of BV and the in-practice guidance for the use of BV.
本妥昔单抗（BV）是一种强效抗体药物偶联物，靶向CD30抗原。由于在CD30阳性淋巴瘤（如霍奇金淋巴瘤和系统性间变性大细胞淋巴瘤）中显示出显著疗效，BV于2011年获得美国食品药品监督管理局加速批准。此后，在各种情况下进行了许多大规模试验，从而扩大了最初的适应证范围。本综述的目的是描述BV临床试验的最新进展以及BV使用的实际指导。
